This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.
Age between 0 and 25 years at the time of initial diagnosis
Diagnosis of rhabdomyosarcoma confirmed histologically
Care at the Oscar Lambret Center between January 2005 and November 2024
No objection to the re-use of data and biological samples collected as part of care for research activities.
Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;
Patient under guardianship or trusteeship.
Oscar Lambret Center (Lille, France)
Case-only
Retrospective
None AHT
Other interventionThis study does not involve any interventions. It analyzes pre-existing biological samples (FFPE tumor tissue) and clinical data from patients with rhabdomyosarcoma.
Spatial Proteomic Profiling of Tumor Samples
Evaluate the ability to obtain distinct proteomic profiles from at least 75% of tumor samples analyzed, with a minimum of two distinct profiles identified per sample.
Click on the lead sponsor to view all of their trials.
Lille University
Lead sponsor
Centre Oscar Lambret, Lille, France
Collaborator
